AngioDynamics (ANGO) Q1 2027 earnings summary

Executive summary

• Q1 FY27 net sales were $80.915M, up 6.9% YoY; Med Tech grew 13.2%, and adjusted EBITDA rose to $5.0M from $2.2M.

• Gross margin expanded 410 bps to 59.4%; GAAP net loss narrowed to $7.097M from $10.903M.

• Auryon delivered its 21st consecutive quarter of double-digit growth; NanoKnife also grew on record prostate procedure volumes and probe demand.

Financial highlights

• Net sales were $80.915M versus $75.711M; operating loss narrowed to $7.302M from $10.656M.

• GAAP net loss was $7.097M, or $0.17/share, versus $10.903M, or $0.26/share; adjusted net loss was $1.8M, or $0.04/share, versus $4.2M, or $0.10/share.

• Adjusted EBITDA was $5.0M versus $2.2M in Q1 FY26.

• Gross margin was 59.4%, up 410 bps YoY, or 57.8% excluding tariff refunds; pricing and Med Tech mix helped, partly offset by manufacturing transition and inflation.

• Operating expenses were $55.342M versus $52.513M; R&D was $7.979M, or 9.9% of sales.

Outlook and guidance

• FY27 guidance was reiterated: net sales of $336M–$341M, Med Tech growth of 12%–15%, Med Device sales flat, and gross margin of 54%–55%.

• FY27 adjusted EBITDA guidance is $13M–$16M; adjusted EPS guidance is a loss of $0.29–$0.24.

• Positive operating cash flow is expected for FY27; Med Tech is expected to exceed half of revenue during the year.

• FY27 tariff impact is expected to be broadly similar to FY26 based on current conditions; gross margin is expected to be lower in H2 than H1.